HIV infection
Infectious disease · 2005–2019
24decisions
17medicines
1carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| darunavir with cobicistat with emtricitabine and tenofovir alafenamide Treatment of human immunodeficiency virus (HIV) infection in adults and adolescents ≥40 kg, for both treatment-naïve patients and treatment-experienced… | Nov 2019 | Recommended with restriction | none received |
| dolutegravir/rilpivirine Treatment of virologically suppressed HIV-infected patients. The fixed dose combination is indicated for use in virologically suppressed patients switching… | Jul 2018 | Recommended with restriction | none received |
| tenofovir alafenamide / emtricitabine / rilpivirine Treatment of human immunodeficiency virus (HIV) infection in treatment-naïve and treatment-experienced patients. | Jul 2016 | Deferred | none received |
| emtricitabine + tenofovir alafenamide Treatment of human immunodeficiency virus (HIV) infection in treatment-naïve and treatment-experienced patients, administered in combination with other… | Nov 2016 | Recommended with restriction | no section in document |
| darunavir/cobicistat Treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents in patients who have experienced virological failure… | Nov 2015 | Not recommended | input received |
| dolutegravir + abacavir + lamivudine Treatment of HIV infection in antiretroviral treatment naïve patients aged 12 years or older weighing 40 kg or more, as well as in patients who have previously… | Nov 2014 | Recommended with restriction | none received |
| cobicistat Treatment of HIV-infected patients as a pharmacokinetic enhancer of atazanavir. | Jul 2013 | Not recommended | no section in document |
| cobicistat + elvitegravir + emtricitabine + tenofovir Treatment of HIV infection in patients with CD4 count less than 500 per cubic millimetre or symptomatic HIV disease, in both treatment-naïve and… | Mar 2013 | Recommended with restriction | no section in document |
| antiretroviral therapy (ART) — combination regimens Initial and continuing treatment of HIV infection in antiretroviral-naïve patients, with removal of the CD4+ count restriction (previously <500 cells/mm³) to… | Nov 2013 | Noted | unclear |
| dolutegravir Treatment of HIV infection in combination with other antiretroviral agents in patients with CD4 count less than 500 cells/mm³ or symptomatic HIV disease, and… | Nov 2013 | Recommended | no section in document |
| tenofovir disoproxil fumarate with emtricitabine and rilpivirine hydrochloride treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per… | Nov 2011 | Recommended with restriction | no section in document |
| tenofovir disoproxil fumarate with emtricitabine and rilpivirine hydrochloride Treatment of human immunodeficiency virus (HIV) infection in treatment-naïve adult patients and as continuing treatment in patients who have previously… | Nov 2011 | Recommended with restriction | no section in document |
| darunavir treatment in combination with other antiretroviral agents, and co-administered with 100 mg ritonavir once daily, of HIV infection in a protease inhibitor naïve… | Jul 2010 | Not recommended | no section in document |
| darunavir Treatment of HIV infection in combination with other antiretroviral agents and co-administered with 100 mg ritonavir once daily, in protease inhibitor naïve… | Jul 2010 | Not recommended | no section in document |
| tenofovir disoproxil fumarate with emtricitabine and efavirenz Treatment of HIV infection in patients with CD4 cell counts of less than 500 per cubic millimetre or viral load of greater than 10,000 copies per mL. | Nov 2009 | Recommended with restriction | no section in document |
| raltegravir Treatment, in combination with other antiretroviral agents, of HIV infection in antiretroviral experienced patients with evidence of HIV replication (viral… | Mar 2008 | Recommended with restriction | no section in document |
| darunavir Treatment, in combination with other antiretroviral agents and co-administered with 100 mg ritonavir twice daily, of HIV infection in antiretroviral treatment… | Jul 2007 | Recommended with restriction | no section in document |
| darunavir Treatment, in combination with other antiretroviral agents and co-administered with 100 mg ritonavir twice daily, of human immunodeficiency virus (HIV)… | Jul 2007 | Recommended | no section in document |
| tipranavir Treatment, in combination with other antiretroviral agents and co-administered with 200 mg ritonavir twice daily, of HIV infection in antiretroviral… | Mar 2007 | Recommended with restriction | no section in document |
| tipranavir Treatment, in combination with other antiretroviral agents and co-administered with 200mg ritonavir twice daily, of HIV infection in antiretroviral experienced… | Jul 2006 | Not recommended | no section in document |
| tipranavir Treatment of HIV infection in combination with other antiretroviral agents in antiretroviral-experienced patients with evidence of viral replication and/or low… | Jul 2006 | Not recommended | no section in document |
| abacavir sulfate with lamivudine Treatment of HIV infection in combination antiretroviral therapy in patients over 12 years of age weighing 40 kg or more with CD4 cell counts less than 500 per… | Jul 2005 | Recommended | no section in document |
| tenofovir disoproxil fumarate with emtricitabine Treatment of HIV infection in patients with CD4 cell counts of less than 500 per cubic millimetre or viral load of greater than 10,000 copies per mL. | Nov 2005 | Recommended | no section in document |
| tenofovir disoproxil fumarate with emtricitabine Treatment of HIV infection in patients with: (a) CD4 cell counts of less than 500 per cubic millimetre; or (b) viral load of greater than 10,000 copies per mL. | 2005 | Recommended with restriction | no section in document |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 6 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.